(Q42989240)

12 November 2017

1 reference

title

Review article: interferon and hepatitis C--factors predicting therapeutic outcome (English)

1 reference

12 November 2017

1 reference

Mabee CL

1

1 reference

12 November 2017

Crippin JS

series ordinal

2

1 reference

12 November 2017

Lee WM

series ordinal

3

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

Alimentary Pharmacology & Therapeutics

12 November 2017

published in

1 reference

12 November 2017

volume

12

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

509-518

1 reference

Clinical outcomes after transfusion-associated hepatitis C.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Measuring hepatitis C viremia in clinical samples: can we trust the assays?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Mechanisms of action of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Hepatitis C virus liver disease in women infected with contaminated anti-D immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Serum lipids in infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Prediction of response to interferon treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Clinical study of IgA antibody against hepatitis C virus core antigen in patients with type C chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Clinical evaluation of titration of hepatitis C virus core antibody and its subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Quantitation of anti-hepatitic C virus antibodies in interferon-treated patients by S29-1/S4 ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

IgM antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of liver disease in patients with acute or chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Hepatocellular expression of HLA-A, B, C molecules predicts primary response to interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Serum levels of soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Cytotoxic T cells and viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to alpha-interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

T-lymphocyte subpopulations as factors predicting clinical response to interferon in hepatitis C virus-related chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Interferon therapy for chronic non-A non-B and chronic delta liver disease in haemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Interferon-alpha therapy for chronic hepatitis C in special patient populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Predictors of response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Hepatitis C virus-RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: evidence for viral replication in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

A proposed system for the nomenclature of hepatitis C viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Factors useful in predicting the response to interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

The hypervariable region of the HCV genome changes sequentially during the progression of acute HCV infection to chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Hepatitis C virus after interferon treatment has the variation in the hypervariable region of envelope 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Variations of hepatitis C virus NS5B sequence (nucleotides 8261-8566) do not correlate with response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.1998.00328.X

10.1046/J.1365-2036.1998.00328.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference